Article
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Pathology, research and practice - 1 Dec 2021
Jain Ekta, Sharma Shivani, Aggarwal Aditi, Bhardwaj Nitin, Dewan Aditi, Kumar Abhishek, Jain Deepika, Bhattacharya Munmun, Saurav Gauraw Kumar, Kini Lata, Mohanty Sambit Kumar
Abstract excerpt
BACKGROUND: Immunotherapy with checkpoint inhibitor programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies targeting the cellular immune checkpoints is the present area of interest showing promising results in patients with advanced non-small cell lung cancer (NSCLC). As there is paucity of PD-L1 expression data from the Indian perspective, we studied the correlation of clinicopathologic...
Topics
- Adult
- Aged
- Aged, 80 and over
- B7-H1 Antigen
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Female
- Humans
- India
- Lung Neoplasms
